Abstract
Frontotemporal dementia usually begins before the age of 65 years. It is manifested by behavioral and language disorders. The lesions observed in frontotemporal dementia affect the frontal and temporal lobes bilaterally. One third of patients have a psychiatric diagnosis at the onset of disease. The genetic component is important: 30-50% of patients have a family history of this disease. Cholinergic effects are not associated with frontotemporal dementia and therefore anticholinesterase treatment is not indicated.
MeSH terms
-
Adenosine Triphosphatases / genetics
-
Aged
-
Aged, 80 and over
-
Alzheimer Disease / diagnosis
-
Amyotrophic Lateral Sclerosis / complications
-
Aphasia, Primary Progressive / complications
-
Brain / diagnostic imaging
-
Cell Cycle Proteins / genetics
-
Dementia* / complications
-
Dementia* / diagnostic imaging
-
Dementia* / drug therapy
-
Dementia* / genetics
-
Dementia* / therapy
-
Diagnosis, Differential
-
Fluoxetine / therapeutic use
-
Frontal Lobe*
-
Humans
-
Microtubule-Associated Proteins / genetics
-
Middle Aged
-
Parkinsonian Disorders / complications
-
Selective Serotonin Reuptake Inhibitors / therapeutic use
-
Temporal Lobe*
-
Tomography, Emission-Computed, Single-Photon
-
Tomography, X-Ray Computed
-
Trazodone / therapeutic use
-
Valosin Containing Protein
Substances
-
Cell Cycle Proteins
-
Microtubule-Associated Proteins
-
Serotonin Uptake Inhibitors
-
Fluoxetine
-
Adenosine Triphosphatases
-
Valosin Containing Protein
-
Trazodone